Sol-Gel Technologies (SLGL) Return on Capital Employed (2018 - 2026)
Sol-Gel Technologies (SLGL) posted quarterly Return on Capital Employed of 14.2% for Q1 2026, up 19.0% year-over-year from 11.94% in Q1 2025, and down 65.05% quarter-over-quarter from 40.64% in Q4 2025.
Sol-Gel Technologies (SLGL) Return on Capital Employed (2018 - 2026) Analysis & Trends
Sol-Gel Technologies (SLGL) has reported Return on Capital Employed for 9 consecutive years, with 14.2% the latest figure, recorded in Q1 2026.
- In Q1 2026, Return on Capital Employed rose 19.0% year-over-year to 14.2%; the TTM figure through Mar 2026 stood at 14.2% (up 19.0% YoY), while the FY2025 annual figure was 28.22%, up 583.0% from the prior year.
- Return on Capital Employed retreated to 14.2% in Q1 2026 per SLGL's latest filing, from 40.64% in the prior quarter.
- Across five years, Return on Capital Employed topped out at 50.03% in Q1 2022 and bottomed at 30.85% in Q1 2024.
- Historically, Return on Capital Employed has averaged 11.05% across 5 years, with a median of 5.84% in 2024.
- On a YoY basis, Return on Capital Employed climbed as much as 5711 bps in 2022 and fell as far as 6324 bps in 2022.
- Sol-Gel Technologies' Return on Capital Employed stood at 7.49% in 2022, then plunged by 123 bps to 16.67% in 2023, then jumped by 125 bps to 4.13% in 2024, then jumped by 884 bps to 40.64% in 2025, then plunged by 65 bps to 14.2% in 2026.
- Business Quant data shows SLGL's Return on Capital Employed at 14.2% in Q1 2026, 40.64% in Q4 2025, and 25.69% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -55.45% |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.68% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -0.20% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 7.88% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 26.09% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -50.93% |
| 10 | Sol-Gel Technologies | 240.26 Mn | 230.12 Mn | - | 14.20% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 14.20% |
| Dec 31, 2025 | 40.64% |
| Sep 30, 2025 | 25.69% |
| Jun 30, 2025 | 47.37% |
| Mar 31, 2025 | 14.01% |
| Dec 31, 2024 | 4.13% |
| Sep 30, 2024 | 5.84% |
| Jun 30, 2024 | -9.45% |
| Mar 31, 2024 | -30.85% |
| Dec 31, 2023 | -16.67% |
| Sep 30, 2023 | -16.63% |
| Jun 30, 2023 | -11.41% |
| Mar 31, 2023 | 3.86% |
| Dec 31, 2022 | -7.49% |
| Sep 30, 2022 | 33.14% |
| Jun 30, 2022 | 41.39% |
| Mar 31, 2022 | 50.03% |
| Dec 31, 2021 | 55.76% |
| Sep 30, 2021 | 17.10% |
| Jun 30, 2021 | -7.11% |